Docstoc

drug study

Document Sample
drug study Powered By Docstoc
					PERSONAL DATA

NAME: Mary Joy Lumawag Perez AGE: 24 years old Civil status: Single Birthday: May 05, 1985 Address: Camacho Cabcaben Mariveles Date Admitted: Aug. 24, 2009

NAME OF DRUGS

MECHANISM OF ACTION
-Provides elemental iron, an essential component in formation of hemoglobin

INDICATION

CONTRAINDICATION

ADVERSE REACTION
GI: nausea, epigastric pain. Vomiting, constipation, diarrhea, black stools, anorexia. Other:temporar ity stained teeth from suspension and drops.

NURSING CONSIDERATION
>Gi upset may be ealated to dose >between meal doses are prefferable but drug can be given with some foods, although absorption maybe decreased. >enteric-coated products reduce GI upset but also reduce amount of iron absorbed. >check for constipation;record color and amount of stools >monitor hemoglobin level, hematocrit and reticulocyte, count during therapy. >combination products ferrous sequels contain stool softener which help prevent constipation, a common adverse reaction

-contra indicated in patient -iron deficiency
-as supplement during pregnancy with primary hemochromatosis or hemosiderosis, hemolytic anemia (unless patient also has iron deficiency anemia), peptic ulcer disease, regional enteritis, or ulcerative colitis. -contra indicated in those receiving repeated blood transfussion.

GENERIC NAME:
Ferrous fumarate

BRAND NAME:
Femiron, feostat, hemocyte, Ircon, Nephrofer, Novufumart, Palafert, Palafer, Pediatric Dropst, VitronC

NAME OF DRUGS

MECHANISM OF ACTION
>provides elemental iron, an essential component in the formation of hemoglobin.

INDICATION
>iron deficiency >as a supplement during pregnancy

CONTRAINDICATION
>contraindicated in patients with hemosideorosis, primary hemolytic anemia (unless parent also has iron deficiency anemia), peptic ulceration, ulcerative colitis, or regional enteritis and in those receiving repeated blood transfusions. >use cautiously on longterm basis.

ADVERSE REACTION
>nausea, epigastric pain, vomiting, constipation, black stool, diarrhea anorexia >temporarily stained teeth from liquid forms

NURSING CONSIDERATIO N
>GI upset, maybe related to dose >between meal doses are preferable >drug can be given with some foods although absorption maybe decreased >enteric-coated products reduce GI upset but also reduce amount of iron absorbed >monitor hemoglobin level, hematocrit, and reticulocytes, count during therapy

GENERIC NAME:
Ferrous sulfate

BRAND NAME:
Apo-ferrous sulfatet, ED-IN-SOL, Feosol, Fer-gen-sol, Fer-InSol, Fer-Iron

NAME OF DRUGS GENERIC NAME:
Cephalexin Monohydrate

MECHANISM OF ACTION
>first generation Cephalosporin that inhibits cell wall synthesis, promoting osmotic instability, usuallt bactericidal

INDICATION
>respiratory tract, GIT, skin, soft tissue, bone and joint infections and otitis media caused by E. coli and other coliform bacteria, group A beta hemolytic Streptococci, Klebsiella species, proteus mirabilis, S. pneumoniae, and Staphylococci

CONTRAINDICATION
>contraindicated in patients hypersensitive to cephalosporins >use cautiously in patients hypersensitive to penicillin because of possibility of cross sensitivity with other betalactam antibiotics >use cautiously in breastfeeding women and in patients with history of colitis or renal insufficiency.

ADVERSE REACTION
CNS: dizziness, HA, fatigue, agitation, confusion, hallucinations GI: anorexia, diarrhea, N/V, abdominal pain GUT: vaginitis, interstitial nephritis MUSCULOSKE LETAL: Arthritis, arthralgia. Joint pain SKIN: maculopapular and erythematus rashes, urticaria

NURSING CONSIDERATION
>ask patient about past reaction to Cephalosporin or Penicillin therapy and obtain specimen for C&S test before giving start therapy, awaiting results. >to prepare oral suspension at required amount og water to powder in two portions. Shake well after each addition. After mixing, store in ref. mixture will remain stable for 14 days. Keep tightly closed and shake well before use. >if large doses are given or if therapy is prolonged monitor patient for super infection, especially if patient is high-risk.

BRAND NAME:
Apo-Cephalext, Biocef, Keflex, Novo-Lexint, Nucephalext

Assessment
S>”Masakit ang tahi ko”, as verbalized by the patient. O>afebrile >redness at the site of pain >with a 5 score in a 0-10 pain scale >difficulty in movement >No edema noted

Nursing Diagnosis
>acute pain related to perineal trauma during laor anddelivery

Planning
After 3 hours of nursing intervention, patient’s level of pain will be reduced from 5-3 on a 0-10 pain scale.

Intervention
>Take and record VS

Rationale

Evaluation

>perform pain assessment

>To serve as Short-term goal is met. baseline data The patient’s level of >to serve as pain decreases from 5baseline date 3 on a 0-10 pain scale

>application of cold compress on perineal area

>provide diversional activities

>reduces inflamation of perineal area thereby reducing pain >utilizing the gain control of pain diversion of attention closes the gain og pain pathway thereby reduing pain perception

Assessment
S>”Hirap akong magpasuso”,as verbalized by the patient O>with symmetrical breast >with poor production of breast milk >with bulging breasts

Nursing Diagnosis
Ineffective breast-feeding related to lack of knowledge and motivation regarding breast-feeding

Planning
After 2 hours of nursing intervention, the patient’s breast will be able to do proper breastfeeding

Intervention
>take and record VS

Rationale

Evaluation

>to serve as Short-term goal met. baseline data >to make or increase milk production The patient verbalizes no difficulty in breastfeeding.

>demonstrate use of electric piston type breast pump with bilateral collection chamber when necessary >encourage frequent rest periods sharing household or child care

>to facilitate relaxation at feeding time

Assessment

Nursing Diagnosis

Planning
At the end of the 8-hr shift, the patient will move from the head of the bed to the door of the room freely without pain

Intervention
>take and record VS

Rationale
>to serve as baseline data >for differential diagnosis and guide treatment intervention

Evaluation
Short-term goal goal partially met.

S>”Hirap akong Impaired walking maglakad”, as claimed related to pain during by the patient movement O>conscious and coherent >weak in appearane >limping noted >grimace when walking >with grunt in exertion

>assist with review result of mobility testing;timing of walking over fixed distance >encourage active and passive exercise

The patient can only move halfway to the door without pain.

>advance level of exercise, as able to increase endurance


				
DOCUMENT INFO
Shared By:
Stats:
views:7046
posted:12/10/2009
language:English
pages:8
Description: for nursing students